Skip to main content
School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
  • Education
    • Degree Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory
  • School of Medicine Home
  • Department of Urology
  • Research
  • Prostate Cancer Research & Clinical Trials

Emory Urology Prostate Cancer Research & Clinical Trials

BED-PSMA 301

Prospective, Phase 3, Multi-Center, Single-Arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA-7.3 (18F) PET Ligand in Men With Newly Diagnosed Prostate Cancer

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate

  • Candidate for RP with PLND scheduled to undergo the surgical procedure

  • Unfavorable intermediate-risk (Gleason Grade Grouping [GGG] 2 with ≥50% of biopsy cores

  • Positive for PCa and/or >1 Intermediate Risk Factor [T2b; T2c; PSA 10-20] or Any GGG 3) or high-risk or very high-risk disease (per NCCN Guidelines Version 2.2019; PROS-2)

Exclusion Criteria:

  • Patients who are planned to have an x-ray contrast agent or other PET radiotracer

Principal Investigator:

David Schuster, MD

Co-Investigators & Collaborators:

Yoram Baum, MD (Department of Radiology and Imaging Sciences); Christopher Filson, MD; Raghuveer Halkar, MD (Department of Radiology and Imaging Sciences); Shreyas Joshi, MD, MPH; Aaron Lay, MD; Kenneth Ogan, MD; John Pattaras, MD; Martin Sanda, MD



BED-PSMA 302

Prospective, Phase 3, Multi-Center, Single-Arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA-7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy

Inclusion Criteria:

  • History of localized adenocarcinoma of the prostate with prior curative intent treatment, experiencing BCR of PCa, following prior treatment with one or more of the following:
    (a) RP
    (b) RP plus adjuvant RT
    (c) RP plus adjuvant androgen deprivation therapy (ADT)
    (d) external beam radiation therapy
    (e) focal gland therapies (e.g. brachytherapy, high-intensity focused ultrasound [HIFU]).

  • If previously taking ADT, it should have been discontinued at least 16 weeks prior to screening

  • An elevated PSA, clinically suspicious for biochemically recurrent disease:
    – Following RP: initial PSA ≥0.2 ng/mL followed by a subsequent confirmatory PSA value ≥0.2 ng/mL
    – Following RT: nadir +2 ng/mL
    – Following focal gland therapies: nadir +2 ng/mL

Exclusion Criteria:

  • Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan

  • Patients currently receiving ADT

Principal Investigator: 

David Schuster, MD

Co-Investigators & Collaborators: 

Yoram Baum, MD (Department of Radiology and Imaging Sciences); Mehmet Bilen, MD (Department of Hematology and Medical Oncology); Bradley Carthon, MD (Department of Hematology and Medical Oncology); Christopher Filson, MD; Benjamin Fischer-Valuck, MD (Department of Radiation Oncology); Raghuveer Halkar, MD (Department of Radiology and Imaging Sciences); Bruce Hershatter, MD (Department of Radiation Oncology); Ashesh Jani, MD (Department of Radiation Oncology); Shreyas Joshi, MD, MPH; Omer Kucuk, MD (Department of Hematology and Medical Oncology); Aaron Lay, MD; Kenneth Ogan, MD; Sagar Patel, MD (Department of Radiation Oncology); Pretesh Patel, MD (Department of Radiation Oncology); John Pattaras, MD; Martin Sanda, MD



EDRN Upgrading Study

Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading

Inclusion Criteria:

  • Biopsy-proven Gleason 3+3=6 prostate cancer diagnosed within the past two years

  • Patient scheduled for radical prostatectomy

Exclusion Criteria:

  • Gleason score greater than 3+3=6 on any prior prostate biopsy

  • Any treatment other than radical prostatectomy planned for prostate cancer

  • Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy

Principal Investigator: 

Martin Sanda, MD

Co-Investigator & Collaborator: 

John Pattaras, MD



EDRN Pass

Canary Prostate Active Surveillance Study Protocol

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate

  • Clinically localized prostate cancer: T1-2; NX or N0, MX or M0

  • No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy)

  • Prostate biopsy requirements: (A) If diagnosis within one year of baseline visit, participants must have at least one biopsy within at least 10 cores; (B) If diagnosis more than one year prior to baseline visit, participants must have a minimum of two biopsies, one of which must be within two years prior to baseline visit

Exclusion Criteria:

  • Unwillingness or inability to undergo serial prostate biopsy

  • History of other malignancies, except: Adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > five years

Principal Investigator: 

Christopher Filson, MD

Co-Investigators & Collaborators: 

Martin Sanda, MD; John Pattaras, MD



EDRN MRI

EDRN Prostate MRI Biomarker Study and Reference Set

Inclusion Criteria:

  • Men with suspected but undiagnosed prostate cancer
    – Abnormal laboratory test for prostate cancer that indicates elevated risk including:
    – e.g., PSA, - % free PSA, abnormal 4K, PHI, exosome, SelectMDx
    – Elevated PSA velocity
    – Lower PSA value with other risk factors for PCa (e.g., family history)

Exclusion Criteria:

  • Prior diagnosis of prostate cancer

  • Prior prostate biopsy or failure to conduct the study

  • Prior prostate MRI

Principal Investigator: 

Christopher Filson, MD

Co-Investigators: 

Martin Sanda, MD; Aaron Lay, MD; Cara Cimmino, MD



Janssen PROTEUS

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate meeting one of the below criteria:
    – Any combination of Gleason 4+3 and Gleason 4+4 or 5+3 from at least six systemic cores
    – Any combination of Gleason 4+3 and Gleason 4+4 or 5+3 from at least three systemic cores with PSA above or equal to 20
    – Gleason 9 or above in one systemic/targeted core
    – At least two systematic or targeted cores with continuous Gleason 8 or above, each with at least 80% involvement

  • ECOG 0 or 1

  • Able to tolerate androgen deprivation therapy (ADT) for up to one year

Exclusion Criteria:

  • Distant metastasis (clinical stage M1)

  • Prior androgen deprivation therapy (ADT)

Principal Investigator: 

John Pattaras, MD

Co-Investigator & Collaborator: 

Omer Kucuk, MD (Department of Hematology and Medical Oncology)

Department of Urology
  • About
    • Our Faculty
    • Annual Team Awards
    • Give to Emory Urology
  • Education
    • Training Facilities
    • Residency for MDs
    • Residency for PAs
    • Pediatric Urology Fellowship
    • GURS Fellowship in Reconstructive & Plastic Urology
    • Advances in Urology Course
    • William Hollis Cooner Resident Award
    • Resident Academic Achievement Award
    • Distinguished Alumni Award
  • Clinical Programs
    • Conditions Treated
    • Services and Procedures
  • Research & Clinical Trials
    • Bladder Cancer Research & Trials
    • Kidney Cancer Research & Trials
    • Penile Cancer Research & Trials
    • Prostate Cancer Research & Clinical Trials
    • Urinary Incontinence Research & Clinical Trials
    • Urologic Surgery Research & Clinical Trials
    • Research Support Team
  • News
    • 2018-2020 News Highlights
    • 2016-2017 News Highlights
    • 2011-2015 News Highlights
    • Newsletters

How to Enroll

For enrollment information involving Emory Urology trials, please contact a member of our research support staff.

Research Support Staff
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2018 Emory School of Medicine
  • Privacy Policy
  • Emergency Information